BioCentury on BioBusiness,
Monday, August 3, 1998
Coulter's (CLTR) $60 million follow-on, announced on Friday, makes it the first U.S. company to complete a decently sized follow-on since Triangle's $60.4 million offering in April. CLTR sold 2.4 million shares, 400,000 more than it had filed for three weeks ago, at $25 per share. But the company took a $3.875 haircut while on the road show, which took it through the U.S. and Europe. It's not yet known how much of the book was sold outside the U.S.
CLTR is gathering data from a Phase III trial of Bexxar, a monoclonal antibody conjugated to radiolabeled iodine, to treat non-Hodgkin's lymphoma. Idec (IDPH) withdrew a follow-on in March, citing market conditions, even though its Rituxan MAb for non-Hodgkin's lymphoma was already on the market in the U.S. IDPH had fallen 10 percent - to $39.25 from $43.50 - before it pulled the deal. IDPH closed Friday at $23.687.
words displayed of
To read this article, you must be an Archives subscriber. Please choose one of the options below.
All contents Copyright © 1993-2016 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement
. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions
. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
Whether you want an individual subscription or need a global group license, we have the products,
the experience and the customer support that biopharma executives, researchers, investors, service providers,
and industry stakeholders have trusted for nearly two decades.
Let our Subscriber Services team customize the best intelligence package available in the industry to meet your needs.
Free Trial Subscription 4 Weeks of Access
BioCentury's Weekly Business Intelligence Journal
Get a 4-week free trial subscription to BioCentury.
Get 4 Weeks Free
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
close [ X ]